Home › Studies › PRJNA972625
PRJNA972625 SRP437657

Gut mycobiome in Polish melanoma on anti-PD-1 therapy

Changes in gut mycobiome in Polish melanoma patients

164 stool samples from adult and elderly participants in Poland, comparing gut fungal communities in melanoma patients undergoing anti-PD-1 therapy versus healthy donors, in a case-control design. machine-written summary

164 samples · 164 runs · PL · Adult · 2024 · 2.46 Gbp / sample · cohort Gut Mycobiota Dysbiosis Is Associated with Melanom

Sources
✓Sequence archive 1,115○Abstract / description✓Full text 164✓Supplementary tables 215–External resources–User contribution–Human verified

Checked this project's papers and archive records yourself? Mark it human-verified.

what each source gave
✓ Sequence archive1,115 sample values (collection date, country, latitude, location region, longitude, subject id, timepoint)
○ Abstract / descriptionread; no usable statement
✓ Full text164 sample values (location locality) · PMC11861499
✓ Supplementary tables215 sample values (age, sex, timepoint)
– External resourcesnot covered by the external resources we ingest
– User contributionnothing uploaded yet
– Human verifiednot yet checked by a person · I checked this project — verify it
Samples at a glance
1 sampling locations · 1 country
Age
adult119
elderly45
Sex
male60
female33
Country
PL164
Body site
primary164
Sequencing depth per sample · this project all projects
all projects, 0–0.03 Gbp: 25,080 samples (4 %)all projects, 0.03–0.1 Gbp: 17,066 samples (3 %)all projects, 0.1–0.3 Gbp: 29,179 samples (5 %)all projects, 0.3–1 Gbp: 47,044 samples (8 %)this project, 0.3–1 Gbp: 3 samplesall projects, 1–3 Gbp: 124,983 samples (22 %)this project, 1–3 Gbp: 134 samplesall projects, 3–10 Gbp: 253,728 samples (44 %)this project, 3–10 Gbp: 27 samplesall projects, 10–30 Gbp: 72,533 samples (13 %)all projects, 30–100 Gbp: 3,024 samples (1 %)all projects, 100–300 Gbp: 106 samples (0 %)all projects, ≥ 300 Gbp: 9 samples (0 %)project median 2.46 Gbp per sample0130Gbp
Sampling design and relatedness

longitudinal — not resolved

60 of 85 people sampled more than once (135 samples; median 2, up to 3 per person). Schedule stated by the source: “Stool (and blood) sampled at two timepoints per melanoma patient: before anti-PD-1 therapy (BT) and in the third month of treatment (T3).” (time origin: initiation of anti-PD-1 therapy); stated follow-up 3 mo.

How longitudinal and relatedness information is derived

Community composition
Ruminococcoides 7.0%Roseburia 6.2%Prevotella 5.1%Gemmiger 3.3%Blautia_A 3.2%Fusicatenibacter 2.3%Vescimonas 1.9%Phocaeicola 1.7%Coprococcus 1.6%Fimenecus 1.6%Mediterraneibacter 1.5%Hominicoprocola 1.3%not assigned to a genus 12.5%other genera 50.8%

Genera, mean relative abundance over 145 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).

Field coverage
fieldsamplescoverageR1R2R3R4
age_category164 100%
country164 100%164
health_condition0 0%
subject_id160 98%160
collection_date164 100%164
detailed_location164 100%
latitude164 100%164
location_locality164 100%164
location_region164 100%164
longitude164 100%164
timepoint_label159 97%13524
age_at_collection_days98 60%98
sex93 57%93
Papers (2)
  • Exploring correlations between gut mycobiome and lymphocytes in melanoma patients undergoing anti-PD-1 therapy. 2025 PMID 39998665 PMC11861499 own_data
  • Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti-PD-1 Therapy. 2024 PMID 38315788 PMC10985481 unsure
Details
Archive description

Recent research has suggested that the microorganisms inhabiting our gut, collectively known as the gut microbiota, may play a critical role in the development and progression of melanoma. Most research has concentrated on bacteria, while gut fungi are usually neglected. Meanwhile, gut fungi can strongly affect the human body - positively or negatively, depending on the particular species.</p><p>Here we aim to investigate the association between gut mycobiota and melanoma and characterize changes in gut mycobiota during anti-PD-1 therapy. We analyzed 163 stool samples from melanoma patients treated with ICI therapy and 134 stool samples from healthy donors. We found out that the gut mycobiota of melanoma patients is distinct from the gut mycobiota of healthy participants. Melanoma samples were characterized by an increased amount of Candida albicans, Candida dubliniensis, Neurospora crassa, and a slight increase of Thermothielavoides terrestris. At the same time, Saccharomyces cerevisiae and Debaryomyces hansenii were decreased in melanoma samples. We also detected several fungal species whose abundance varied during anti-PD-1 therapy.</p><p>To our knowledge, this is the first study entirely concentrated on the fungal part of the intestinal microbiota of melanoma patients and the first tracking its changes during anti-PD-1 therapy. The findings from this study may provide important insights into the complex interplay between the gut microbiome and cancer, paving the way for the development of novel strategies for the prevention and treatment of melanoma.

How this project entered the registry

Classified as human gut / stool shotgun DNA metagenome of adult by deterministic_prior with confidence 0.90. Assay shotgun_dna.

  • host external_curation.infant_catalog · “infant triage reason_code age_adult_only”
  • body site study.title · “Changes in gut mycobiome in Polish”
  • body site study.description · “microorganisms inhabiting our gut , collectively known”
  • life stage external_curation.infant_catalog · “infant triage reason_code age_adult_only”
Evidence examples (one per field × route)
samplefieldvaluerouteconf.sourcequote
SAMN35084305age_at_collection_days23376R20.85paper.supp.262_2024_3918_MOESM1_ESM.xlsx[S1_Table!Age]64
SAMN35084305collection_date2020R10.90biosample.attribute:collection_date2020
SAMN35084305countryPLR10.90sample.attr.geo_loc_namePoland
SAMN35084305latitude52.4064R10.90biosample.attribute:lat_lon52.4064 N 16.9252 E
SAMN35084305location_localityPoznanR30.70paper.fulltext.methodsPoznan University of Medical Sciences (Poznan, Poland)
SAMN35084305location_regionGreater Poland VoivodeshipR10.60biosample.attribute:lat_lon52.4064 N 16.9252 E
SAMN35084305longitude16.9252R10.90biosample.attribute:lat_lon52.4064 N 16.9252 E
SAMN35084305sexmaleR20.85paper.supp.262_2024_3918_MOESM1_ESM.xlsx[S1_Table!Sex]M
SAMN35084305subject_id0501R10.70sample.name_rule:IDMMP_0501A
SAMN35084305timepoint_labelAR10.70sample.name_rule:IDMMP_0501A
SAMN35084308timepoint_labelBTR20.85paper.supp.262_2024_3918_MOESM1_ESM.xlsx[S1_Table!Time]BT
Sequencing

164 runs over 164 samples · mean 2.42 Gbp per run (median 2.46 Gbp, total 396.23 Gbp; 164 runs with a base count) · layout PAIRED 164 · platform ILLUMINA 164 · models NextSeq 550 (164) · 88% of runs with a Sandpiper profile · first public 2024-07-01

Authors (13)

Szóstak N first · Handschuh L · Samelak-Czajka A · Tomela K · Pietrzak B · Schmidt M · Galus · Mackiewicz J · Mackiewicz A · Kozlowski P · Philips A last · Budnik M · Kaczmarek M

Downloads

PRJNA972625.csv.gz (5.5 KB) · parquet (77.3 KB) — all 164 samples, every field with route and confidence · PRJNA972625_determinations.csv.gz (12.0 KB) — 1,494 evidence rows

Samples (164 · every field this project has values for · hover a cell for its source)
Loading the sample table…